{"entity":{"id":"nct04855656","kind":"trial","name":"Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of Lunresertib run by Debiopharm International SA, now recruiting.","summary":"Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT04855656 by Debiopharm International SA, with 464 participants planned, started 2021-04-30. Conditions recorded: Advanced Solid Tumor. Interventions recorded: Lunresertib, RP-3500 and Zedoresertib.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04855656","url":"https://clinicaltrials.gov/study/NCT04855656"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lunresertib"],"companies":["repare-therapeutics","debiopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04855656","phase":"1","setting":"Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors","sponsor":"Debiopharm International SA","enrolled":464,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04855656/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lunresertib","kind":"drug","name":"Lunresertib","route":"/drugs/lunresertib/"}],"company":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}]}}